Skip to main content
. 2018 Jan 4;15(3):3923–3927. doi: 10.3892/ol.2018.7724

Table II.

Prognostic value of FMO5 expression in OS.

OS

Variables HR (95% CI) P-value
Univariate analysis
  Sex (male vs. female) 0.722 (0.294–1.770) 0.476
  Age, years (≥60 vs. <60)   2.698 (0.625–11.652) 0.184
  Clinical stage (I–II vs. III–IV) 1.809 (0.735–4.453) 0.197
  T stage (T1-2 vs. T3-4)   2.408 (0.555–10.437) 0.240
  N stage (N0 vs. N1-2) 1.633 (0.674–3.956) 0.278
  M stage (M0 vs. M1) 2.706 (1.023–7.162) 0.045
  FMO5 expression (low vs. high) 2.326 (1.062–5.091) 0.035
Multivariate analysis
  Sex (male vs. female) 0.573 (0.231–1.426) 0.231
  Age, years (≥60 vs. <60) 2.451 (0.710–8.464) 0.156
  FMO5 expression (low vs. high) 2.865 (1.116–7.355) 0.029

FMO5, flavin-containing monooxygenase 5; OS, overall survival; HR, hazard ratio; CI, confidence interval.